Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sanofi stock in Canada | $52.43

Own Sanofi shares in just a few minutes.

Sanofi is a drug manufacturers-general business based in the US. Sanofi stocks (SNY.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $51.42 – a decrease of 1.87% over the previous week. Sanofi employs 99,412 staff and has a trailing 12-month revenue of around $36.9 billion.

How to buy Sanofi stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: SNY in this case.
  5. Research Sanofi stocks. The platform should provide the latest information available.
  6. Buy your Sanofi stocks. It's that simple.

How has Coronavirus impacted Sanofi's stock price?

Since the stock market crash in March caused by coronavirus, Sanofi's stock price has had significant positive movement.

Its last market close was $52.43, which is 3.01% up on its pre-crash value of $50.85 and 39.37% up on the lowest point reached during the March crash when the stocks fell as low as $37.62.

If you had bought $1,000 worth of Sanofi stocks at the start of February 2020, those stocks would have been worth $797.24 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,083.73.

Sanofi stock price

Use our graph to track the performance of SNY stocks over time.

Sanofi stocks at a glance

Information last updated 2021-07-22.
Latest market close$52.43
52-week range$43.131 - $54.26
50-day moving average $52.4163
200-day moving average $50.3138
Wall St. target price$65
PE ratio 9.0171
Dividend yield $3.2 (6.21%)
Earnings per share (TTM) $5.7025

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Sanofi stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Sanofi price performance over time

Historical closes compared with the last close of $52.43

1 month (2021-06-25) -0.91%
3 months (2021-04-26) 1.08%

Is Sanofi under- or over-valued?

Valuing Sanofi stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sanofi's P/E ratio

Sanofi's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Sanofi stocks trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.

Sanofi's PEG ratio

Sanofi's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.1072. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Sanofi's EBITDA

Sanofi's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$10.6 billion.

The EBITDA is a measure of a Sanofi's overall financial performance and is widely used to measure a its profitability.

Sanofi financials

Revenue TTM USD$36.9 billion
Operating margin TTM 21.1%
Gross profit TTM USD$25.3 billion
Return on assets TTM 4.19%
Return on equity TTM 20.01%
Profit margin 33.02%
Book value $25.1865
Market capitalisation USD$128.8 billion

TTM: trailing 12 months

How to short and sell Sanofi stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "SNY.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 5.0 million Sanofi stocks held short by investors – that's known as Sanofi's "short interest". This figure is 3.7% up from 4.8 million last month.

There are a few different ways that this level of interest in shorting Sanofi stocks can be evaluated.

Sanofi's "short interest ratio" (SIR)

Sanofi's "short interest ratio" (SIR) is the quantity of Sanofi stocks currently shorted divided by the average quantity of Sanofi stocks traded daily (recently around 1.5 million). Sanofi's SIR currently stands at 3.36. In other words for every 100,000 Sanofi stocks traded daily on the market, roughly 3360 stocks are currently held short.

However Sanofi's short interest can also be evaluated against the total number of Sanofi stocks, or, against the total number of tradable Sanofi stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sanofi's short interest could be expressed as 0% of the outstanding stocks (for every 100,000 Sanofi stocks in existence, roughly 0 stocks are currently held short) or 0.0022% of the tradable stocks (for every 100,000 tradable Sanofi stocks, roughly 2 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Sanofi.

Find out more about how you can short Sanofi stock.

Sanofi stock dividends


Dividend payout ratio: 53.97% of net profits

Recently Sanofi has paid out, on average, around 53.97% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.75% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi shareholders could enjoy a 3.75% return on their shares, in the form of dividend payments. In Sanofi's case, that would currently equate to about $3.2 per share.

Sanofi's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Sanofi's most recent dividend payout was on 26 May 2021. The latest dividend was paid out to all shareholders who bought their stocks by 3 May 2021 (the "ex-dividend date").

Have Sanofi stocks ever split?

Sanofi stocks were split on a 5:1 basis on 30 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi stocks – just the quantity. However, indirectly, the new 80% lower stock price could have impacted the market appetite for Sanofi stocks which in turn could have impacted Sanofi's stock price.

Sanofi stock price volatility

Over the last 12 months, Sanofi's stocks have ranged in value from as little as $43.131 up to $54.26. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi's is 0.4028. This would suggest that Sanofi's stocks are less volatile than average (for this exchange).

Sanofi overview

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site